China’s National Medical Products Administration (NMPA) released the 109th Catalog of Reference Listed Drugs for Chemical Generic Drugs, adding 30 new product specifications and supplementing information for 24 product specifications from previous batches – the latest installment in the regulator’s ongoing expansion of the reference‑drug framework underpinning China’s generic quality and consistency evaluation system.
Policy Snapshot
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Document | 109th Catalog of Reference Listed Drugs (RLD) for Chemical Generic Drugs |
| Release Date | 20 Sep 2026 |
| New Additions | 30 product specifications |
| Supplemental Updates | 24 product specifications from previous batches |
| Product Details | Specific drugs, strengths, and dosage forms added – not disclosed in the release summary |
| Next Steps | Continued periodic catalog updates; future batches expected on a rolling basis |
Catalog Context – The Reference Listed Drug Framework
- Function: The Reference Listed Drug (RLD) catalog designates the originator or reference products against which domestic chemical generics must demonstrate quality and efficacy consistency – the foundation of China’s generic consistency evaluation regime.
- Why It Matters: Inclusion in the catalog gives generic manufacturers a clear, regulator‑endorsed reference standard for bioequivalence studies and abbreviated approval filings, reducing development uncertainty.
- Supplemental Information: Updates to previously listed specifications – such as corrected or expanded reference details – help align ongoing generic programs with current regulatory records.
- Cadence: The release of the 109th batch reflects a sustained, rolling update process through which the NMPA progressively broadens RLD coverage across therapeutic areas.
- Coverage Details: Cumulative number of listed specifications and therapeutic areas covered by this batch – not disclosed.
Market Impact & Outlook
- Generic Development Pipeline: The 30 newly added specifications unlock defined reference standards for the corresponding products, enabling domestic generic developers to advance consistency evaluation and filing programs with regulatory clarity.
- First‑to‑Market Incentives: Earlier designation of reference drugs tends to accelerate generic entry timelines, intensifying future competition for originator products in the affected categories once generics clear review.
- Procurement Linkage: Products that complete consistency evaluation against catalog references become eligible for China’s centralized drug procurement programs – reinforcing the catalog’s role as a gateway to volume‑based market access.
- Regulatory Transparency: The supplemental updates for 24 prior specifications signal continued housekeeping of the RLD database, reducing mismatches between sponsor records and official reference listings.
- Commercial Specifics: Manufacturers of the newly listed reference products, and the generic companies positioned to benefit – not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding subsequent NMPA catalog releases, generic development timelines, and market expectations arising from the 109th RLD Catalog. Actual outcomes may differ due to risks including the pace of future catalog batches, consistency evaluation and bioequivalence results, approval timelines for generic filings, and competitive and procurement dynamics in China’s pharmaceutical market.-Fineline Info & Tech
